Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2025 09:00 ET | Source: BIOXYTRAN, INC.

Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M

BOSTON, MASSACHUSETTS, May 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel antiviral therapies, today announced...
April 11, 2025 09:30 ET | Source: BIOXYTRAN, INC.

Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements

- The universal oxygen carrier delivery capabilities of BXT-25 can be monitored, broadening its applications to treat hypoxic diseases - Leading drug candidate ProLectin-M targets galectins in viral...
February 21, 2024 08:00 ET | Source: BIOXYTRAN, INC.

Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19

First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology...
September 14, 2023 09:41 ET | Source: BIOXYTRAN, INC.

Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M

BOSTON, MASSACHUSETTS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral...
August 24, 2023 09:00 ET | Source: BIOXYTRAN, INC.

Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials

First Antiviral Drug in Glycovirology BOSTON, MASSACHUSETTS, Aug. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral...
February 28, 2023 08:00 ET | Source: BIOXYTRAN, INC.

ProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial Virus

Activity in Influenza and Respiratory Syncytial Virus highlights the broad- spectrum antiviral potential of ProLectin-M BOSTON, MASSACHUSETTS, Feb. 28, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC....
December 28, 2022 07:00 ET | Source: BIOXYTRAN, INC.

Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial

Trial meets endpoints in safety and efficacyIND Letter from the CDSCO to optimize dosageEstablishment of an Indian Subsidiary to commercialize ProLectin-M BOSTON, MASSACHUSETTS, Dec. 28,...
December 14, 2022 07:00 ET | Source: BIOXYTRAN, INC.

Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization

BOSTON, MASSACHUSETTS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19...
November 22, 2022 08:00 ET | Source: BIOXYTRAN, INC.

Bioxytran, Inc. Announces the Reinitiation of Coverage of Its Stock by Avise Analytics

BOSTON, MASSACHUSETTS, Nov. 22, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet...
August 01, 2022 09:00 ET | Source: BIOXYTRAN, INC.

Novel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 Coronavirus

ProLectin-M, a new class of oral antiviral drug BOSTON, MASSACHUSETTS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (Symbol: BIXT) (the “Company”), a clinical stage biotechnology...